Brookline Capital Management Predicts XFOR FY2024 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Analysts at Brookline Capital Management dropped their FY2024 earnings per share estimates for shares of X4 Pharmaceuticals in a research note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of ($0.67) for the year, down from their prior estimate of ($0.62). The consensus estimate for X4 Pharmaceuticals' current full-year earnings is ($0.50) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals' Q4 2024 earnings at ($0.16) EPS, FY2025 earnings at ($0.78) EPS, FY2026 earnings at ($0.27) EPS and FY2027 earnings at $0.42 EPS.

Several other brokerages have also commented on XFOR. HC Wainwright dropped their price target on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a "buy" rating for the company in a research report on Thursday, November 14th. Stifel Nicolaus cut their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, November 14th.

X4 Pharmaceuticals Trading Down 9.4 %

XFOR traded down $0.07 during midday trading on Thursday, hitting $0.64. The company's stock had a trading volume of 1,942,549 shares, compared to its average volume of 1,899,290. The firm has a market cap of $108.52 million, a P/E ratio of -7.07 and a beta of 0.14. X4 Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $1.60. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. The firm has a 50-day moving average price of $0.55 and a two-hundred day moving average price of $0.62.

Institutional Investors Weigh In On X4 Pharmaceuticals

Large investors have recently made changes to their positions in the business. State Street Corp increased its holdings in X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company's stock valued at $1,976,000 after purchasing an additional 189,105 shares in the last quarter. Ensign Peak Advisors Inc boosted its position in shares of X4 Pharmaceuticals by 4.6% in the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company's stock worth $1,477,000 after buying an additional 111,032 shares during the period. Point72 Asset Management L.P. grew its stake in shares of X4 Pharmaceuticals by 15.1% in the third quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company's stock valued at $418,000 after buying an additional 81,968 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of X4 Pharmaceuticals during the 3rd quarter valued at about $340,000. Finally, K2 Principal Fund L.P. acquired a new position in X4 Pharmaceuticals during the 2nd quarter worth approximately $284,000. Institutional investors and hedge funds own 72.03% of the company's stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.